phloretin has been researched along with Carcinoma, Hepatocellular in 5 studies
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Phloretin can inhibit BEL-7402 cells' malignant pheotype." | 1.35 | [Study on the effect of phloretin on inhibiting malignant pheotype of BEL-7402 cells]. ( Chen, J; Liu, JQ; Luo, H; Wang, YJ, 2008) |
| "Human hepatocellular carcinoma specimens and HepG2 show a high level of GLUT2 transporter activity in the cell membrane." | 1.35 | In vitro and in vivo study of phloretin-induced apoptosis in human liver cancer cells involving inhibition of type II glucose transporter. ( Ho, YS; Lee, CH; Lin, SY; Liu, RS; Tsai, CY; Tseng, H; Wang, YJ; Wei, PL; Wu, CH, 2009) |
| "Phloretin is an inhibitor of the mammalian glucose transporter and the iodothyronine-5'-deiodinase." | 1.28 | Phloretin inhibits cellular uptake and nuclear receptor binding of triiodothyronine in human hep G2 hepatocarcinoma cells. ( Movius, EG; Phyillaier, MM; Robbins, J, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saraswati, S | 1 |
| Alhaider, A | 1 |
| Abdelgadir, AM | 1 |
| Tanwer, P | 1 |
| Korashy, HM | 1 |
| Luo, H | 1 |
| Wang, YJ | 2 |
| Chen, J | 1 |
| Liu, JQ | 1 |
| Wu, CH | 1 |
| Ho, YS | 1 |
| Tsai, CY | 1 |
| Tseng, H | 1 |
| Wei, PL | 1 |
| Lee, CH | 1 |
| Liu, RS | 1 |
| Lin, SY | 1 |
| Guo, W | 1 |
| Huang, N | 1 |
| Cai, J | 1 |
| Xie, W | 1 |
| Hamilton, JA | 1 |
| Movius, EG | 1 |
| Phyillaier, MM | 1 |
| Robbins, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Research on Effectiveness and Safety of the Treatment, Hyperthermic Intraperitoneal Chemotherapy Combined With Tislelizumab and Targeted Therapy, That is Used for High-risk Hepatocellular Carcinoma After R0 Resection[NCT05546619] | 30 participants (Anticipated) | Interventional | 2022-08-01 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 other studies available for phloretin and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resista | 2019 |
[Study on the effect of phloretin on inhibiting malignant pheotype of BEL-7402 cells].
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Hepatocellular; Cell Adhesion; Cell Line, Tumor; Cell | 2008 |
In vitro and in vivo study of phloretin-induced apoptosis in human liver cancer cells involving inhibition of type II glucose transporter.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Caspases; Cell Proliferation; Cell | 2009 |
Fatty acid transport and metabolism in HepG2 cells.
Topics: beta-Cyclodextrins; Biological Transport, Active; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell | 2006 |
Phloretin inhibits cellular uptake and nuclear receptor binding of triiodothyronine in human hep G2 hepatocarcinoma cells.
Topics: Carbonyl Cyanide m-Chlorophenyl Hydrazone; Carcinoma, Hepatocellular; Cell Line; Cell Nucleus; Gluco | 1989 |